Advancements in Novel Immunotherapeutics in The Oncology Battle Aethlon Medical (NASDAQ: AEMD) announced the independent DSMB completed a safety review of cohort 2 in its AEMD-2022-06 trial on March 24, 2026 and recommended advancing to cohort 3. No device-related SAEs or DLTs were reported and cohort 3 enrollment is open to receive three Hemopurifier treatments over one week.The study (9–18 patients) evaluates safety, feasibility and dose-finding in patients with solid tumors receiving pembrolizumab or nivolumab, with primary endpoints focused on adverse events and safety labs.

#AEMD Advancements in Novel Immunotherapeutics in The Oncology Battle

www.stocktitan.net/news/AEMD/advancements-i...

Aethlon Medical, Inc. Advances to Final Cohort in Oncology Clinical Trial Following Positive DSMB Review SAN DIEGO, March 24, 2026/ PRNewswire/-- Aethlon Medical, Inc., a clinical-stage biotechnology company developing the investigational Aethlon Hemopurifier ®, an extracorporeal device for oncology and other indications, today announced that the independent Data Safety Monitoring Board overseeing its ongoing clinical trial AEMD-2022-06 has completed...

#AEMD Aethlon Medical, Inc. Advances to Final Cohort in Oncology Clinical Trial Following Positive DSMB Review

www.stocktitan.net/news/AEMD/aethlon-medica...

Aethlon Medical Engages Maxim Group LLC to Evaluate Strategic Opportunities Aethlon Medical (Nasdaq: AEMD) has engaged Maxim Group LLC as exclusive financial advisor to evaluate strategic opportunities including partnerships, mergers, acquisitions or other transactions.The company completed the second cohort of its Australian oncology trial and will submit safety data to the independent Data Safety Monitoring Board. No timeline or assurance of a transaction has been established.

#AEMD Aethlon Medical Engages Maxim Group LLC to Evaluate Strategic Opportunities

www.stocktitan.net/news/AEMD/aethlon-medica...

Fundamental analysis of $AEMD (AETHLON MEDICAL INC) based on financial data and reported results.

#AEMD

Aethlon Medical Announces Pricing of a Private Placement and Warrant Inducement, Priced At-The-Market for Aggregate Gross Proceeds of $3.3 Million The combined effective offering price for each share of common stock and accompanying warrants is $4.03. The warrants will have an exercise price of $4.03 per share, will be exercisable upon shareholder approval, and will expire on the five and one-half year anniversary from such date of shareholder approval. Pursuant to a warrant inducement agreement, the...

#AEMD Aethlon Medical Announces Pricing of a Private Placement and Warrant Inducement, Priced At-The-Market for Aggregate Gross Proceeds of $3.3 Million

www.stocktitan.net/news/AEMD/aethlon-medica...

ID: Photo of the book’s cover, featuring wrought iron gates against a night sky. A candle burns in the light fitting hanging from one of the stone gateposts, obscuring the moon in a way that makes the candle seem to be lighting up the sky. On the gateposts are classical statues of a woman on one side and a warrior on the other

#nowreading the Arden Early Modern Drama edition of PHILASTER, by Francis Beaumont and John Fletcher, edited by Suzanne Gossett #jacobean #play #malewriter #femalewriter #aemd @bloomsburyacad.bsky.social

#AEMD: Can Increased Treatments Extend, Further Improve Positive Patient Responses? buff.ly/hFqPLpp

Aethlon Medical Announces Fiscal Q2 2025 Financial Results and Corporate Update Aethlon Medical (Nasdaq: AEMD) reported fiscal Q2 results for the period ended September 30, 2025 and provided a corporate update on clinical and research programs.Key financials include $5.8M cash, a 48% reduction in operating expenses to ~$1.5M for the quarter, and an operating loss of $1.5M vs $2.8M year-ago. Clinical progress includes recruitment of Cohort 2 in the Australian oncology Hemopurifier trial and early biomarker changes observed in 3 initial participants. Collaboration with UCSF on Long COVID EV analysis and an evaluation of Hemopurifier compatibility with a simplified blood treatment system were also announced.

#AEMD Aethlon Medical Announces Fiscal Q2 2025 Financial Results and Corporate Update

www.stocktitan.net/news/AEMD/aethlon-medica...

Aethlon Medical to Release Fiscal Second Quarter Financial Results and Host Conference Call on November 12, 2025 Aethlon Medical (Nasdaq: AEMD) will release fiscal second quarter results for the period ended September 30, 2025 on Wednesday, November 12, 2025 at 4:15 p.m. ET. Management will host a conference call the same day at 4:30 p.m. ET to review results and recent corporate developments, followed by a Q&A.Registered participants will receive dial-in instructions; toll-free and international dial-in numbers are provided. A replay will be available approximately one hour after the call through December 12, 2025 via the company website or provided dial-in numbers (replay ID 1454680).The release reiterates that Aethlon is advancing the investigational Hemopurifier, an extracorporeal device targeting enveloped viruses and tumor-derived extracellular vesicles, and notes its U.S. FDA Breakthrough Device Designation for specified oncology and viral indications.

#AEMD Aethlon Medical to Release Fiscal Second Quarter Financial Results and Host Conference Call on November 12, 2025

www.stocktitan.net/news/AEMD/aethlon-medica...

#AEMD: Early Oncology Trial Data Looks Promising buff.ly/MItHtJF

#AEMD: Oncology Trial Advances as Early Data Looks Promising buff.ly/VsZk3jU

Biotech and Medical Tech Stocks Report Breakthrough Clinical Trial Updates Investorideas.com, a go-to investing platform covering biotech and medtech stocks releases an industry snapshot looking at recent clinical trial updates, featuring Aethlon Medical, Inc. (NASDAQ: AEMD), a medical

#AEMD Biotech and Medical Tech Stocks Report Breakthrough Clinical Trial Updates

www.stocktitan.net/news/AEMD/biotech-and-me...

Aethlon Medical's Hemopurifier® shows Changes in Extracellular Vesicles, Extracellular MicroRNAs, and T Cell Numbers in Australian Oncology Clinical Trial Aethlon Medical (Nasdaq: AEMD) reported preliminary biological changes from the first cohort (3 patients) in its Australian safety, feasibility and dose‑finding oncology trial of the Hemopurifier.Key observations after a single 4‑hour Hemopurifier treatment: decreases in large EVs and platelet‑derived EVs in two patients, EV PD‑L1 decreased in all three, 7 of 10 microRNAs decreased in two patients, and increases in total T cells, CD8, CD4 and tumor‑specific (CD137+) T cells were noted. EV and microRNA levels generally returned to baseline within 1–3 weeks.The company emphasized caveats: a 3‑patient cohort with one withdrawal, single treatments only, directional descriptive results only, and no claim of clinical efficacy or dose response without larger trials.

#AEMD Aethlon Medical's Hemopurifier® shows Changes in Extracellular Vesicles, Extracellular MicroRNAs, and T Cell Numbers in Australian Oncology Clinical Trial

www.stocktitan.net/news/AEMD/aethlon-medica...

Leading Indicators, Thursday September 4, 2025 – Crystal Equity Research

Small-cap stocks gapping down in trading, Thu Sept 4th - #ARTL #SDST #PPBT #NEON #CRMT #AEMD #DOLE #DAVA #CAL #AAMI - More: crystalequityresearch.com/leading-indi... - #smallcap

Aethlon Medical Announces Pricing of $4.5 Million Public Offering Aethlon Medical (Nasdaq: AEMD), a medical therapeutic company focused on cancer and infectious disease treatments, has announced the pricing of a $4.5 million public offering. The offering consists of 5,000,000 shares of common stock (or pre-funded warrants) and warrants to purchase up to 5,000,000 additional shares at a combined price of $0.90 per share.The accompanying warrants will have an exercise price of $0.90 per share, exercisable immediately with a five-year expiration term. The offering, expected to close around September 5, 2025, is being managed by Maxim Group LLC as the exclusive placement agent. Proceeds will fund general corporate purposes, including clinical trials, R&D, and working capital.

#AEMD Aethlon Medical Announces Pricing of $4.5 Million Public Offering

www.stocktitan.net/news/AEMD/aethlon-medica...

Innovation and IP in Medtech Stocks - How Patents Build Leaders Investorideas.com, a go-to investing platform covering biotech and medtech stocks releases an industry snapshot looking at innovation and the importance of IP in medtech,, featuring Aethlon Medical, Inc.

#AEMD Innovation and IP in Medtech Stocks - How Patents Build Leaders

www.stocktitan.net/news/AEMD/innovation-and...

Breakthrough Long COVID Treatment Patent: Aethlon's Hemopurifier Targets Persistent Spike Proteins Aethlon Medical receives US and EU patents for Hemopurifier device treating Long COVID and COVID-associated coagulopathy. Patents extend protection until 2042, targeting spike protein removal.

#AEMD #AEGM Aethlon Medical Announces Issuance of Hemopurifier® Patents for the Treatment of Long COVID and COVID-19-associated Coagulopathy (CAC)

www.stocktitan.net/news/AEMD/aethlon-medica...

BREAKING NEWS: ( NASDAQ: #AEMD ) PRISM Mid-Day Movers: Beauty Sector Earnings Pressure

📢 Stocks Trending NOW: #WMT #THAR #NEGG #AEMD #BA #APM #CRWV #EVOK #GRO #NIO

#AEMD: Cohort 2 Enrollment Open; Initial Cohort 1 Data Analysis Expected Next Month buff.ly/XrPPQit

Aethlon's Cancer Treatment Device Proves Safe in First Trial Phase, Slashes Operating Costs by 32% Medical device company reports successful safety data from cancer trial first cohort, 98.5% efficacy in preclinical studies, while reducing expenses by $800,000. See full results.

#AEMD Aethlon Medical Announces Financial Results for the Fiscal First Quarter Ended June 30, 2025, and Provides Corporate Update

www.stocktitan.net/news/AEMD/aethlon-medica...

Breakthrough Device Maker Aethlon Medical Announces Q1 Earnings Call: Cancer Treatment Progress Update Expected FDA Breakthrough-designated Hemopurifier maker reveals Q1 2025 financials Aug 13. Join conference call for latest cancer treatment progress. Register now.

#AEMD Aethlon Medical to Release Fiscal First Quarter Financial Results and Host Conference Call on August 13, 2025

www.stocktitan.net/news/AEMD/aethlon-medica...

ID: The book’s cover, showing domestic wrought iron security gates, with a glimpse of the doors they protect. The doors are open, as is the left-hand gate, letting light spill through onto the cobblestones in front of the house. This artfully overexposed light obscures our view into the house

#nowreading the Arden Early Modern Drama edition of John Webster’s THE DUCHESS OF MALFI, edited by Leah S Marcus #ardenearlymoderndrama #aemd #malewriter #femalewriter #jacobean #play @bloomsburyacad.bsky.social

#AEMD: No SAEs in Cohort 1 Post-Hemopurifier Treatment; Progressing Trial to Cohort 2 buff.ly/jY57yBs

Aethlon Medical, Inc. Announces Positive Data Safety Monitoring Board Review and Recommendation to Advance to Next Clinical Trial Cohort Aethlon Medical (Nasdaq: AEMD) announced positive safety review results from the independent Data Safety Monitoring Board (DSMB) for its ongoing clinical trial AEMD-2022-06 of the Aethlon Hemopurifier®. The trial is evaluating the device's safety and optimal dosing in cancer patients with stable or progressive disease while on Pembrolizumab or Nivolumab treatment.The DSMB reviewed data from the initial three-patient cohort, who each received a single 4-hour Hemopurifier treatment, finding no safety concerns or serious adverse events. The board recommended advancing to Cohort 2, where participants will receive two Hemopurifier treatments over one week. The trial aims to enroll 9-18 patients across three Australian clinical sites. The study targets patients among the 60-70% who don't respond well to anti-PD-1 immunotherapy, with findings intended to inform future Premarket Approval studies.

#AEMD Aethlon Medical, Inc. Announces Positive Data Safety Monitoring Board Review and Recommendation to Advance to Next Clinical Trial Cohort

www.stocktitan.net/news/AEMD/aethlon-medica...

#AEMD: Progressing & Expanding Clinical & Pre-Clinical Activities in Cost Efficient Manner buff.ly/ZZNRCbz

PRISM Mid-Day Movers: Robotic Medical Innovation and Disappointing Earnings Diverge Indices
#NanoVibronix Inc. ( #NAOV)
#AethlonMedical Inc. ( #AEMD)
#INmuneBio, Inc. ( #INMB)
#HeliusMedicalTechnologies, Inc. ( #HSDT)
#AdialPharmaceuticals, Inc. ( #ADIL)

prismmarketview.com/prism-mid-da...

Aethlon Medical Stock Jumps 20 Percent on Q4 Results and Progress in Cancer Trial Aethlon Medical (Nasdaq: AEMD) shares rose 20 percent following the release of its fiscal fourth quarter 2025 results, highlighting initial progress in its ongo

#AethlonMedical (Nasdaq: #AEMD) released its Q4 results and shared major clinical progress, including patient treatments in its Hemopurifier® cancer trial, regulatory approval in India, and new data supporting expanded use in #LongCOVID.
prismmarketview.com/aethlon-medi...

Aethlon Medical's Cancer Trial Breakthrough: 3 Patients Complete Novel Hemopurifier Treatment as Long COVID Study Advances New clinical data reveals Hemopurifier success in cancer trial. See how Aethlon's 98.5% EV removal rate could transform immunotherapy outcomes. Get latest trial insights.

#AEMD Aethlon Medical Announces Financial Results for the Fiscal Fourth Quarter Ended March 31, 2025, and Provides Corporate Update

www.stocktitan.net/news/AEMD/aethlon-medica...